Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clarity Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.94 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
316.08 million
Earnings per share
-0.118
Dividend per share
N/A
Year To Date Return
297.02%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clarity Pharmaceuticals Ltd (ASX: CU6)
Latest News
Healthcare Shares
2 ASX biotech shares that could be the next Telix Pharmaceuticals
Share Gainers
Why Clarity Pharmaceuticals, Life360, Ramsay Health Care, and Spartan Resources shares are rising today
Share Gainers
Why Catapult, Clarity, Pro Medicus, and Qantas shares are rising today
Share Gainers
3 ASX All Ords shares smashing new multi-year highs while the market sinks
Healthcare Shares
Up 200% in 6 months, guess which ASX All Ords stock just hit another all-time high
Share Gainers
Why Clarity Pharmaceuticals, DroneShield, IGO, and Serko shares are surging
Share Fallers
Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today
Share Market News
Why this exciting ASX biotech stock could be a future star
Healthcare Shares
1 ASX stock to consider buying that could be the next ResMed
Healthcare Shares
Why this ASX biotech stock could rise a massive 40%
Share Gainers
This ASX healthcare stock turned $20k into $140,000 in less than 2 years
Healthcare Shares
3 pharma shares outshining the ASX index today
CU6 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CU6 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $6.06 | $-0.21 | -3.35% | 2,510,783 | $6.23 | $6.44 | $6.04 |
| 19 Nov 2024 | $6.27 | $0.23 | 3.81% | 1,836,365 | $6.14 | $6.40 | $6.07 |
| 18 Nov 2024 | $6.04 | $-1.10 | -15.41% | 2,065,542 | $7.10 | $7.10 | $5.92 |
| 15 Nov 2024 | $7.14 | $0.06 | 0.85% | 804,757 | $7.18 | $7.30 | $6.96 |
| 14 Nov 2024 | $7.08 | $0.02 | 0.28% | 603,168 | $7.17 | $7.17 | $6.82 |
| 13 Nov 2024 | $7.06 | $-0.40 | -5.36% | 955,115 | $7.46 | $7.68 | $7.00 |
| 12 Nov 2024 | $7.46 | $-0.02 | -0.27% | 675,216 | $7.33 | $7.60 | $7.30 |
| 11 Nov 2024 | $7.48 | $0.28 | 3.89% | 918,846 | $7.29 | $7.60 | $7.29 |
| 08 Nov 2024 | $7.20 | $0.19 | 2.71% | 788,125 | $7.12 | $7.34 | $6.95 |
| 07 Nov 2024 | $7.01 | $-0.34 | -4.63% | 1,054,895 | $7.39 | $7.44 | $6.87 |
| 06 Nov 2024 | $7.35 | $0.20 | 2.80% | 1,098,445 | $7.22 | $7.58 | $7.17 |
| 05 Nov 2024 | $7.15 | $0.16 | 2.29% | 509,009 | $7.05 | $7.19 | $6.91 |
| 04 Nov 2024 | $6.99 | $0.23 | 3.40% | 994,565 | $7.01 | $7.25 | $6.87 |
| 01 Nov 2024 | $6.76 | $-0.07 | -1.02% | 636,159 | $6.74 | $6.80 | $6.65 |
| 31 Oct 2024 | $6.83 | $-0.02 | -0.29% | 1,755,116 | $6.83 | $7.05 | $6.58 |
| 30 Oct 2024 | $6.85 | $-0.32 | -4.46% | 1,270,918 | $7.06 | $7.20 | $6.80 |
| 29 Oct 2024 | $7.17 | $-0.10 | -1.38% | 830,903 | $7.22 | $7.25 | $6.96 |
| 28 Oct 2024 | $7.27 | $0.11 | 1.54% | 988,560 | $7.10 | $7.28 | $7.07 |
| 25 Oct 2024 | $7.16 | $0.46 | 6.87% | 1,594,792 | $6.75 | $7.30 | $6.73 |
| 24 Oct 2024 | $6.70 | $0.01 | 0.15% | 983,189 | $6.57 | $6.72 | $6.51 |
| 23 Oct 2024 | $6.69 | $-0.08 | -1.18% | 1,076,045 | $6.77 | $6.82 | $6.48 |
| 22 Oct 2024 | $6.77 | $0.21 | 3.20% | 1,543,328 | $6.50 | $6.86 | $6.48 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Oct 2024 | Michelle Parker | Buy | 542,710 | $495,000 |
Exercise of options. vwap
|
| 02 Oct 2024 | Michelle Parker | Exercise | 600,000 | $495,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Christopher Roberts | Exercise | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Christopher Roberts | Buy | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Buy | 1,083,776 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Colin Biggin | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Colin Biggin | Buy | 1,084,321 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Thomas Ramdahl | Buy | 200,000 | $165,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Thomas Ramdahl | Exercise | 200,000 | $165,000 |
Exercise of options. vwap
|
| 17 Sep 2024 | Rosanne Robinson | Buy | 178,079 | $165,000 |
Exercise of options.
|
| 17 Sep 2024 | Rosanne Robinson | Exercise | 200,000 | $165,000 |
Exercise of options.
|
| 07 Aug 2024 | Colin Biggin | Buy | 905,625 | $605,000 |
Exercise of options. vwap
|
| 07 Aug 2024 | Colin Biggin | Exercise | 1,000,000 | $605,000 |
Exercise of options. vwap
|
| 01 Aug 2024 | Alan Taylor | Buy | 543,002 | $363,000 |
Exercise of options.
|
| 01 Aug 2024 | Alan Taylor | Exercise | 600,000 | $363,000 |
Exercise of options.
|
| 01 Aug 2024 | Colin Biggin | Exercise | 600,000 | $363,000 |
Exercise of options. VWAP
|
| 01 Aug 2024 | Colin Biggin | Buy | 542,835 | $363,000 |
Exercise of options. VWAP
|
| 20 May 2024 | Robert Thomas | Buy | 8,333 | $35,706 |
On-market trade.
|
| 20 May 2024 | Robert Thomas | Buy | 7,575 | $32,291 |
On-market trade.
|
| 29 Apr 2024 | Robert Thomas | Issued | 17,425 | $44,433 |
Rights issue.
|
| 29 Apr 2024 | Robert Thomas | Issued | 16,667 | $42,500 |
Rights issue.
|
| 21 Mar 2024 | Thomas Ramdahl | Exercise | 400,000 | $242,000 |
Exercise of options.
|
| 21 Mar 2024 | Thomas Ramdahl | Buy | 400,000 | $242,000 |
Exercise of options.
|
| 12 Dec 2023 | Alan Taylor | Issued | 1,764,981 | $1,596,400 |
Issue of options. Black - Scholes model, VWAP
|
| 12 Dec 2023 | Colin Biggin | Issued | 928,988 | $840,846 |
Issue of options. Black-Scholes, VWAP, As per announcement on 14-12-2023
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Mar 2016 |
Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He is member of Risk Committee.
|
| Ms Rosanne Elizabeth Robinson | Lead Independent DirectorNon-Executive Director | Oct 2010 |
Ms Robinson brings experience in the nuclear field and a range of commercial and operational expertise to the Group. She has over 25 years of experience in senior leadership and governance roles in public and private companies and government. She is member of Risk Committee.
|
| Dr Alan John Taylor | Executive ChairmanExecutive Director | Nov 2013 |
Dr Taylor has over 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory.
|
| Dr Colin David Biggin | Chief Executive OfficerManaging Director | Oct 2019 |
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
|
| Ms Michelle Parker | Executive Director | Sep 2024 |
Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia
|
| Mr Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
|
| David Green | Chief Financial Officer |
-
|
|
| Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 22,818,280 | 7.23% |
| UBS Nominees Pty Ltd | 19,336,534 | 6.12% |
| Cabbit Pty Ltd Atf Robwill Trust | 17,911,280 | 5.67% |
| J P Morgan Nominees Australia Pty Limited | 16,935,337 | 5.36% |
| T M Ventures Pty Ltd | 16,699,842 | 5.29% |
| HSBC Custody Nominees (Australia) Limited | 14,248,257 | 4.51% |
| A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C | 13,266,660 | 4.20% |
| Argo Investments Limited | 9,802,322 | 3.10% |
| Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C | 8,040,000 | 2.55% |
| Vantres Pty Ltd Atf Asten Super Fund A/C | 6,812,340 | 2.16% |
| Boorris Pty Ltd Atf Boorris Trust | 6,065,800 | 1.92% |
| BNP Paribas Noms Pty Ltd | 5,356,049 | 1.70% |
| Pacific Custodians Pty Limited | 5,280,485 | 1.67% |
| Smarter Capital Pty Ltd | 5,004,543 | 1.58% |
| National Nominees Limited | 4,438,511 | 1.41% |
| Kylaco Pty Ltd | 3,896,280 | 1.23% |
| Bnp Paribas Nominees Pty Ltd | 3,713,550 | 1.18% |
| Australian Nuclear Science & Technology Organisation | 3,599,920 | 1.14% |
| Colin Biggin | 3,249,764 | 1.03% |
| Wyargine Holdings Pty Ltd Atf Shellcove Super Fund | 3,210,425 | 1.02% |
